ASTELLAS PHARMA INC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital
Article By: The Life Sciences Report
Thursday, March 3, 2016 7:53 AM EDT
Eden Rahim of Toronto-based Next Edge Capital describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot.
In this article: LLY, MBXBF, IBB, BIIB, REPCF, XLV, BCLI, AXON, CPHR, NTRP, SGYP, ACAD, MDVN, PTLA, ITCI, ALPMF
Read
Brean Capital Weighs In On Medivation Following Update On Terrain Study
Article By: TipRanks
Thursday, March 26, 2015 5:53 PM EDT
Medivation is best known for developing therapies to treat serious diseases. Earlier in 2014 the biopharmaceutical company received FDA approval to expand the use of Xtandi, a prescription medicine used to treat men with prostate cancer.
In this article: MDVN, ALPMF
Read
U.S. FDA Approves New Indication For The Use Of XTANDI Capsules For Patients With Metastatic Castration-Resistant Prostate Cancer
Article By: Dr. Hung Tran
Thursday, September 11, 2014 9:31 AM EDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC).
In this article: ALPMF, MDVN
Read

PARTNER HEADLINES

Latest Tweets for $ALPMF

No tweets yet!